Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside

Abstract

In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China. This virus rapidly spread worldwide and was declared a global pandemic by the World Health Organization (WHO) in March 2020. High incidence, long incubation period, and diverse clinical signs of the disease posed a huge challenge globally. The efforts of health systems have been focused on repurposing existing drugs or developing innovative therapies to reduce the morbidity and mortality associated with SARS-CoV-2. In addition, most of the large pharmaceutical companies are intensely working on vaccine development to swiftly deliver safe and effective vaccines to prevent further spread of the virus. In this review, we will discuss the latest data on therapeutic strategies undergoing clinical trials. Additionally, we will provide a summary of vaccines currently under development.

Keywords • Coronavirus • COVID-19 • Immunization • Passive • Cell- and tissue-based therapy • COVID-19 vaccines

Introduction

In December 2019, a cluster of patients with pneumonia emerged in Wuhan (China) as a result of the novel coronavirus (2019-nCoV).1 The reported cases were identified in Wuhan’s seafood market.2 The virus is officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). According to the report by the National Health Commission of China, the virus can transmit from human to human, chiefly via respiratory particles.3 Soon after, the disease rapidly spread to other countries to such an extent that in January 2020, the World Health Organization (WHO) declared it the sixth public health emergency of international concern, and in March 2020 as a global pandemic.4

Common symptoms of COVID-19 are fever and dry cough. Epidemiological studies have indicated that people with comorbidities and the elderly are more vulnerable to the disease.2 SARS-CoV-2 belongs to the beta coronavirus of group 2B and causes the disease by infecting host cells through angiotensin-converting enzyme 2 (ACE2) receptors.1, 5 This virus is a member of the same family as the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), which have caused outbreaks of epidemic proportions in the past two decades.2, 5 Currently, most of the treatments are based on repurposing existing drugs and supportive therapy. The most
important pathophysiological processes of COVID-19 include high virus load, hyper-inflammation, and tissue damage. To date, multiple therapeutic strategies have been planned based on inhibiting at least one of these mechanisms.

Due to the importance of preventing the spread of the virus, many pharmaceutical companies have put all their efforts into developing novel COVID-19 vaccines with high safety and efficacy. The present review provides the latest achievements in therapeutic strategies such as pharmacotherapy, cell therapy, and convalescent plasma therapy. Finally, candidate vaccines in development are summarized.

Pathogenesis of COVID-19

The SARS-CoV-2 virus infects the lower respiratory tract and causes pneumonia. However, clinical signs and mortality rates are lower than with MERS and SARS. SARS-CoV-2 infection is divided into three phases, namely (i) asymptomatic state, (ii) upper airway and conducting airway response, and (iii) hypoxia, ground-glass infiltrates, and progression to acute respiratory distress syndrome (ARDS).4, 7

Phase I: Asymptomatic State (Initial 1-2 Days of Infection)

Infected host cells are mediated by the interaction between the spike (S) protein of the virus and ACE2, the primary receptor for SARS-CoV-2 located in the lungs. In vitro studies on SARS-CoV have indicated that the ciliated cells are the primary target cells in the conducting airways. Due to the limited spread of the virus, the immune response is weak in this phase. Although the viral load is low in this stage, people are infected, and the virus can already be detected using polymerase chain reaction (PCR). Samples are taken using the throat or nasal swabs; however, nasal swabs might be more sensitive than throat swabs.8

Phase II: Upper Airway and Conducting Airway Response (Next Few Days)

The virus spreads to the lower respiratory tract and triggers a robust immune response. Infected cells secrete interferon and the levels of some cytokines, such as C-X-C motif ligand 10 (CXCL10), increase. CXCL10 has also been reported to be useful as a disease marker in SARS. The disease is mild in this phase and is limited to the airways. Patients are monitored and treated at home.8

Phase III: Hypoxia, Ground-glass Infiltrates, and Progression to ARDS

In this phase, the virus reaches the respiratory exchange units of the lung and infects type II pneumocytes. About 20% of the infected people enter this phase and can become seriously ill. Virus involvement in host cells leads to cell death and tissue damage. In addition, lymphopenia occurs at this stage due to the infection of T cells and macrophages by the virus.4 In severe cases with high viral load, patients develop ARDS.4, 8 The main reason for ARDS is the cytokine storm, an uncontrolled release of pro-inflammatory cytokines (particularly interleukin (IL)-16), which leads to tissue damage and organ failure.5 Immunopathogenesis of coronavirus is depicted in figure 1.10

Therapeutic Strategies for COVID-19

Pharmacotherapy

In terms of disease pathogenesis, different therapeutic agents have been suggested based on targeting viral replication and tissue damage associated with cytokine storms. The spectrum of therapeutics for COVID-19 is evolving rapidly. Most of the efforts have focused on repurposing the existing drugs to reduce the morbidity and mortality associated with virus complications. In the following section, we summarize the current evidence for pharmacotherapy in patients with confirmed COVID-19.

Chloroquine and Hydroxychloroquine

Chloroquine and hydroxychloroquine are being used worldwide for about 70 years, and are part of the WHO Model List of Essential Medicines. They have a long-standing history in the prevention and treatment of malaria and the treatment of chronic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).11, 12 These drugs can exert antiviral effects by different mechanisms. Since they are weak base therapeutic agents, they can, for example, increase endosomal pH in host intracellular organelles, resulting in inhibition of autophagosome-lysosome fusion and inactivation of enzymes required for replication.13 Additionally, they can affect the glycosylation of ACE2.14 Different doses of both drugs have been suggested to treat patients with confirmed COVID-19. However, the latest report from Tang and colleagues showed no beneficial effects in COVID-19 patients.15 Moreover, a meta-analysis reported that hydroxychloroquine is associated with increased mortality in COVID-19 patients, and chloroquine had no beneficial effects.16

Ribavirin

Ribavirin is a guanine analog that inhibits viral RNA-dependent RNA polymerase (RdRp)
activity. Ribavirin has previously been used to treat patients with SARS and MERS. In MERS, ribavirin (generally combined with interferons) demonstrated no tangible effect on clinical outcomes or viral clearance. Ribavirin was also used to treat SARS (in combination with other drugs such as corticosteroids), and no conclusive results were obtained. Recent studies have shown no significant difference in mortality rates and length of hospital stay between the group treated with ribavirin and the control group.

Lopinavir/Ritonavir
Lopinavir/ritonavir is a combination drug for the treatment of human immunodeficiency virus (HIV). In 2003, the drug showed inhibitory activity against SARS-CoV in vitro via inhibition of 3CL protease, a critical enzyme for virus replication. Several systematic review meta-analyses have shown that lopinavir/ritonavir has no significant effect on the recovery of patients with COVID-19.

Remdesivir
Remdesivir is an antiviral drug, an adenosine analog, which exerts its effect by binding to the viral RdRp leading to inhibition of viral replication. Remdesivir was synthesized by Gilead Sciences in 2017 for the treatment of Ebola virus disease. In vitro studies have shown that remdesivir could inhibit coronaviruses such as SARS-CoV and MERS-CoV replication. Remdesivir is the only antiviral drug approved by the American Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adult and pediatric patients. To date, many clinical trials have evaluated the use of remdesivir for the treatment of COVID-19. Although some studies have reported the ineffectiveness of remdesivir, most completed clinical trials strongly recommend the use of remdesivir in hospitalized patients.

For instance, an adaptive COVID-19 treatment trial (a randomized, double-blind, placebo-controlled trial) has shown that remdesivir could shorten the time to recovery, and the positive effects of remdesivir were confirmed in the hospitalized patients on supplemental oxygen. It is noteworthy that the safety and efficacy of co-administration of remdesivir and corticosteroids have not been thoroughly evaluated in clinical trials. However, there are theoretical arguments in favor of the beneficial effects of such a combination therapy in some patients with severe COVID-19. Therefore, it can be used as adjuvant therapy in severe patients who require supplemental oxygen.

Baricitinib is a selective Janus kinase (JAK) 1 and 2 inhibitors capable of inhibiting the pathways of cytokine production. Baricitinib combined with...
remdesivir were shown to be more effective than remdesivir alone in reducing recovery time with no serious side effects in patients receiving high-flow oxygen or noninvasive ventilation (clinical trial: NCT04401579). According to preliminary reports, remdesivir can be used in pregnant patients. It has been reported that among 86 pregnant and postpartum hospitalized patients with severe COVID-19, remdesivir therapy was well tolerated, and the rate of serious side effects was low.

**Favipiravir**

Favipiravir is an antiviral agent that inhibits the RdRp of the virus, similar to remdesivir. Favipiravir is effective against a wide range of influenza viruses. Most of the preclinical data on favipiravir are derived from its anti-influenza and anti-Ebola activity. There are a few studies on the efficacy of favipiravir in COVID-19. In a two-arm, open-label control study, patients with laboratory-confirmed COVID-19 were divided into two groups, namely patients in the favipiravir arm received oral favipiravir (day 1: 1,600 mg twice daily, days 2-14: 600 mg twice daily) plus IFNα, and in the control arm were treated with lopinavir/ritonavir plus IFN-α. According to this study, favipiravir showed considerably better therapeutic effects on patients with COVID-19 in terms of disease progression, viral clearance, and improvement in chest imaging (91.43% versus 62.22%) than the control group. Furthermore, the favipiravir arm showed fewer adverse reactions than the control arm. In contrast, a clinical trial revealed that favipiravir was ineffective in treating patients with COVID-19 and reducing the viral load.

**Janus Kinase (JAK) Inhibitors**

JAK inhibitors can exert an anti-inflammatory effect by interfering with the signal transduction leading to immune stimulation and inflammation. Therefore, immunosuppression induced by JAK inhibitors can potentially reduce the hyper-inflammation observed in COVID-19 patients. Moreover, JAK inhibitors, particularly baricitinib, can directly possess antiviral properties by inhibiting endocytosis of the virus. A systemic review meta-analysis concluded that JAK inhibitors could significantly reduce mortality risk in hospitalized patients with COVID-19. According to the COV-BARRIER trial, baricitinib combined with corticosteroids could significantly decrease mortality. In addition, tofacitinib may be an appropriate alternative in the absence of baricitinib, as it exhibited beneficial effects in the STOP-COVID clinical trial. As a result, baricitinib and tofacitinib are recommended by the American National Institutes of Health (NIH) to manage inflammation in hospitalized patients requiring high-flow oxygen or noninvasive ventilation. It should be noted that other JAK inhibitors cannot be administered to patients except in clinical trials. Because of the potential for fetal malformations, the risks of use in pregnant patients must be weighed against the potential benefits.

**Adjunctive Therapies**

**Corticosteroids**

The main reason for using corticosteroids is to reduce host inflammatory responses in the lungs, resulting in ARDS. However, this benefit may be outweighed by undesired side effects, including increased risk of secondary infection and delayed viral clearance. It has been reported that corticosteroids did not improve outcomes during the SARS and MERS outbreaks, but delayed viral clearance and increased the rate of secondary infections. In a clinical study of 31 COVID-19 patients, 11 received corticosteroids. The results showed that corticosteroid therapy had no considerable effect on virus clearance time, hospital length of stay, and duration of symptoms. Corticosteroids can however reduce pulmonary fibrosis in patients with severe ARDS and avoid progressing pathological deterioration, the reason why some patients with SARS infection benefited from corticosteroids. Evidence showed that a low-to-moderate dose of corticosteroids (e.g., methylprednisolone) may increase survival in COVID-19 patients with clinical indications such as refractory ARDS, sepsis, or septic shock. A large multicenter open-label randomized controlled trial conducted in the United Kingdom reported that the administration of up to 10 days of dexamethasone combined with standard care significantly reduced mortality in patients on mechanical ventilation or requiring supplemental oxygen on admission. In contrast, in another study, patients requiring supplemental oxygen on admission did not benefit from dexamethasone administration. Based on many clinical trials, NIH recommended short-term low-to-moderate dose administration of corticosteroids as adjuvant therapy to improve the survival of patients with severe COVID-19. However, a randomized clinical trial showed that an early high-dose of steroids could preserve pulmonary fibrosis and long-term pulmonary consequences in critically ill patients. Therefore, more studies are needed to determine the most effective steroids dose. As in non-pregnant patients, administration of a short course of dexamethasone is recommended for...
hospitalized pregnant patients due to reduced maternal mortality and low risk of fetal adverse effects.50

**Monoclonal Antibodies**

As mentioned, the S protein on the surface of SARS-CoV-2 mediates the entry of the virus into the host cell by binding to ACE2. Specific monoclonal antibodies (mAbs) that block the S protein can act as an effective agent in preventing the spread of the virus and host infection.51 Since the onset of the COVID-19 pandemic, several of these mAbs have been the subject of clinical trials.52 In November 2020, FDA authorized the emergency use of bamlanivimab to treat mild to moderate COVID-19 patients over the age of 12 with chronic diseases. Bamlanivimab is not recommended for hospitalized patients, because its beneficial effects have not been proven and may even aggravate the symptoms of the disease. It should therefore only be prescribed in the early stages of the disease. The current recommended dose is a 700 mg single dose as an intravenous infusion over at least 60 minutes.53 Reported side effects of bamlanivimab, similar to other mAbs, include allergic reactions, pain, and bruising at the injection site.54 Several clinical studies have been performed on its efficacy. These studies have shown that patients who receive bamlanivimab are more likely to survive and are less likely to need hospitalization. For example, a study of 1,392 patients with mild to moderate COVID-19 showed that the mortality rate (1.7% vs. 2.8%) and hospitalization (6.4% vs. 14.8%) were higher in the control group than in the bamlanivimab group.55

IL-6 appears to be a key inflammatory cytokine in inducing systemic inflammation and hypoxic respiratory failure in COVID-19 patients.56 IL-6 receptor-inhibiting mAbs block IL-6-mediated signaling by competitively binding to both soluble and membrane-bound IL-6 receptors.57 Several randomized clinical trials demonstrated that tocilizumab, an IL-6 receptor inhibitor, in combination with standard COVID-19 care improved the recovery time and had clinical benefits.58-60 Other IL-6 receptor inhibitors such as siltuximab and sarilumab have also shown promising results for treating patients with COVID-19. According to the NIH guideline, sarilumab and tocilizumab can be used only in combination with a course of dexamethasone or an alternative corticosteroid in the hospitalized patients requiring supplemental oxygen, high-flow oxygen, noninvasive ventilation, or invasive mechanical ventilation. Although there are no data on the use of these mAbs during pregnancy, they can be indicated in pregnant patients considering the safe use of other immunoglobulins G (IgG) mAbs in this target population.61

**Stem Cell-based Therapies**

Regenerative medicine is another approach that can be applied to reduce the complications of COVID-19. Stem cells offer a promising method to suppress coronavirus lethality. The capacity of mesenchymal stem cells (MSCs) in inhibiting hyper-inflammation has been revealed in the animal model of the influenza virus.52 MSCs exhibit anti-inflammatory and immune-regulatory effects by concurrent activation of T lymphocytes and provoking macrophages’ differentiation into anti-inflammatory macrophages and regulatory T cells.63 MSCs can decrease IL1α, TNFa, IL-6, IL-12, and IFNγ concentration in the lungs and prevent a cytokine storm.63, 64 In addition, these cells reduce the level of hydrogen peroxide production by neutrophils and thus prevent further activation of the immune cells. MSCs are useful in both acute and chronic lung injury.65 According to a recent study, MSCs were able to reduce acute lung injury and ischemia-reperfusion caused by lipopolysaccharide.66 Interestingly, the immunomodulatory function of MSCs can be potentiated by cytokines produced by lymphocytes.67 MSCs can modify the abnormal function of both innate and adaptive immune responses, such as hyper-inflammation and lymphopenia.68, 69

The safety and efficacy of MSCs have been confirmed in clinical studies. In a recent study, lymphocyte count was augmented and inflammatory markers decreased in patients treated with MSCs. In addition, levels of the anti-inflammatory cytokine IL-10 were elevated too.70 Moreover, regeneration of damaged tissues caused by COVID-19 can be improved by immunomodulatory, regenerative, pro-angiogenic, and anti-fibrotic properties of MSCs.71 Due to complications of stem cell therapy, secreted exosomes from stem cells can be utilized instead of cell therapy.72 Exosomes are extracellular vesicles secreted by different cells, which play an essential role in cell communication. MSCs-derived exosomes contain various macromolecules which can participate in the regulation of immune cell function.72 Altogether, stem cell-based therapy is a promising approach to COVID-19 treatment, but more large-scale trials are needed.

**Convalescent Plasma Therapy**

The use of convalescent plasma (CP) or hyper-immune immunoglobulin is one of the potential
promising adjuvant therapies for patients with COVID-19. The rationale for using human blood products in the treatment of COVID-19 emanated from its use in the H1N1 influenza pandemic in 2009, during which patients derived a clinically significant mortality benefit and improved viral clearance by using blood products. Duan and colleagues observed a significant clinical improvement in 10 COVID-19 patients treated with convalescent plasma transfusion, leading to complete viremia resolution in seven days. These results suggest that CP may be a promising option for the treatment of COVID-19, but more randomized trials are needed.

CP refers to passive antibodies obtained from individuals who have recovered from COVID-19, especially those with an adequate titer of neutralizing antibodies (NAbs) in their plasma. According to previous findings on various viral respiratory diseases, CP can be utilized as an effective and emergency treatment for COVID-19 to confer immediate immunity to severe patients and decrease the viral load. It was shown that administration of CP with a higher titer of IgG antibody decreased the risk of mortality compared to CP with a lower titer. Two studies supported these findings. One concluded that CP reduced the mortality rate among the patients, and the other found an inverse correlation between transfusion of CP and deaths occurring within 14 days after transfusion. IgG level after CP administration could be a promising parameter for measuring treatment success in immunosuppressed patients who are at the early stage of the infection and have no detectable IgG.

Some studies demonstrated that CP therapy in COVID-19 patients can considerably improve disease symptoms and clinical parameters such as pulmonary lesions. They also reported that CP can be used for prophylactic purposes by minimizing the virulence of the illness through the neutralization of virus antigens with particular antibodies, thereby reducing the mortality rate. After CP administration, antibodies (especially NAbs) increase in a time-dependent manner in the recipients. These antibodies bind to the viral particles and neutralize them by blocking access to host target cells. Furthermore, other antibody action pathways such as antibody-mediated cellular cytotoxicity, complement activation, and phagocytosis can promote the effect of CP. Plasma contains not only NAbs, but also non-neutralizing antibodies such as IgG and IgM, which can contribute to prophylaxis and recovery enhancement through binding to the virus, but the presence of NAbs is critical.

A recent randomized study showed that although CP was utilized extensively in treating severe COVID-19, no significant clinical improvement was observed in the treatment group. Besides, it was reported that CP could not reduce the risk of mortality in moderate to severe COVID-19 patients, while there are even uncertainties about its effect on mild and asymptomatic patients. Therefore, more studies are required to clarify uncertainties about CP therapy. Despite the mentioned benefits, CP has some limitations, such as a lack of standardization, availability, and clinical evidence to advocate its efficacy.

**Designed Vaccine**

Vaccination is the most promising approach to stop and control infection. Recently, due to the outbreak of COVID-19, the need for an effective vaccine against SARS-CoV-2 has become extremely urgent. Most pharmaceutical companies and academic institutions worldwide have focused on developing vaccines against SARS-CoV-2. By October 2021, 128 vaccine candidates have undergone clinical trials, and 194 are in the pre-clinical phase. The only COVID-19 vaccines approved by the WHO are Pfizer-BioNTech, Moderna, Janssen, Sinopharm, Sinovac, and AstraZeneca COVID-19 (table 1). Vaccine technology has been considerably improved in recent years. It includes RNA and DNA vaccines, recombinant protein vaccines, live vector vaccines, whole-cell inactivated vaccines, live-attenuated vaccines, and subunit vaccines. The type and percentage of COVID-19 vaccine candidates under clinical trials are presented in figure 2.

**COVID-19 Vaccines Under Development**

**Whole Virus Vaccines**

Live-attenuated or inactivated whole virus vaccines are a classic strategy to induce the secretion of immune effectors against the virus. A major advantage of whole virus vaccines is the stimulation of toll-like receptors (TLRs), including TLR 3, TLR 7/8, and TLR 9. Live-attenuated vaccines can elicit both humoral and cellular immune responses. These vaccines are easily produced, and typically two doses provide a strong lifelong immune response. Live virus vaccines are shown to cause some complications, including lung damage and infiltration of eosinophils in a mouse model and liver injury in ferrets. Therefore, this type of vaccine needs extensive additional testing to prove its safety. However, inactivated vaccines produce a lesser immune response than live-attenuated vaccines, and adjuvants are required.
Therapeutic strategies for COVID-19 patients

It is notable that Sinopharm and Sinovac, recently approved by the WHO, are based on an inactivated virus platform.

**Subunit Vaccine**

Subunit vaccines contain one or more antigens that can induce a strong immune response. Almost all subunit vaccines contain S protein as the immunogenic agent to activate the immune system to prevent interaction with the host ACE2 receptor. Several institutions have started programs on the COVID-19 subunit vaccine. For instance, the University of Queensland is synthesizing a subunit vaccine based on the “molecular clamp” technology to expose viral surface protein more easily to the immune system. Clover Biopharmaceuticals is using their patented Trimer-Tag® technology to produce a recombinant COVID-19 S protein subunit-trimer vaccine (S-Trimer) via a rapid mammalian cell-culture based expression

---

**Table 1: A Summary of the WHO-approved SARS-CoV-2 vaccine candidates**

| Vaccine type   | Name                  | Developer                                                                 | Antigen                                      | Immunogenicity in human | Number of doses | Schedules          |
|---------------|-----------------------|---------------------------------------------------------------------------|----------------------------------------------|-------------------------|-----------------|--------------------|
| Inactivated virus vaccine | BBIBP-CorV           | Beijing Institute of Biological Products, Sinopharm, and Institute of Viral Disease Control and Prevention | The whole virus                             | 79%                     | 2               | Day 0 and day 21    |
|                | CoronaVac (formerly PiCoVac) | Sinovac Biotech and National Institute for Communicable Disease Control | The whole virus                             | 51%                     | 2               | Day 0 and Day 14    |
| Adenoviral vector vaccine | AZD1222 (also known as ChAdOx1) | The University of Oxford and AstraZeneca                                | Full-length spike protein                    | 63-90%                 | 2               | Day 0 and day 60 or 90 |
|                | Ad26.COV2.S           | Johnson&Johnson and Beth Israel Deaconess Medical Center                 | -                                            | 85.4%                  | 1-2             | Day 0 or day 0 and day 56 |
| mRNA vaccine   | Comirnaty (also known as tozinameran or BNT162b2) | Pfizer and BioNTech                                                      | Full-length spike protein with two proline substitutions | Very high (95%)        | 2               | Day 0 and day 21    |
|                | mRNA-1273            | Moderna                                                                   | Full-length spike protein with two proline substitutions | Very high (94.5%)      | 2               | Day 0 and day 28    |

**Figure 2: The pie chart shows the type and percentage of COVID-19 vaccine candidates currently under clinical trials.**
systems. Moreover, Novavax published that they have produced virus-like nano-particles based on S protein. However, some studies have reported that the SARS full-length S proteins can increase infectivity and eosinophilic infiltration. In a recent study, it has been demonstrated that SARS-CoV-2 receptor-binding domain (RBD) protein has the potential to enhance cross-reactive or cross-neutralizing antibodies against SARS-CoV-2 or SARS-CoV and also inhibits the virus entry into ACE2 expressing host cells by blocking these receptors. For instance, ZF2001 is a subunit vaccine using a dimeric form of the RBD of the S protein. According to the phase I and II trials, ZF2001 was well tolerated and immunogenic. Indeed, using RBD as an antigen can provide high protective immunity, but also minimize hyperactivation of the immune system, the adverse effect of full-length S protein.

**Nucleic Acid Vaccines**

mRNA vaccines represent a promising approach to vaccine development. This type of technology is based on transferring mRNA encoded viral antigen into host cells. Then, host cells express antigens and activate immune cells. The advantages of mRNA vaccines include high efficiency, capacity for rapid expansion, and potential for low-cost fabrication and safe administration. Considering the achieved clinical success, mRNA vaccines developed by Pfizer-BioNTech and Moderna were approved by the FDA. DNA vaccines usually contain plasmid DNA molecules that encode immunogenic antigens. Providing drug product stability is easier to achieve in DNA vaccines than in mRNA vaccines. However, they may increase the risk of mutations in the host genome as the result of vector integration. So far, two SARS-CoV-2 DNA vaccines are under development. INO-4800 and AG0302-COVID19 are DNA plasmid vaccines encoding SARS-CoV-2 S protein, which are under phase 2/3 clinical trials (NCT04642638 and NCT04655625).

**Synthetic Peptide or Epitope Vaccine**

In contrast to subunit vaccines, these vaccines contain certain antigen fragments and usually cause low immunogenicity. To increase the ability of these vaccines to stimulate the immune system, structural modifications, delivery systems, and adjuvants are needed. However, they are easier to produce than other types of vaccines. Recently, a group of scientists has discovered a highly conserved set of B and T cell epitopes from S and nucleocapsid (N) proteins of SARS-CoV-2 that may be useful in developing an epitope vaccine against COVID-19. Currently, Generex Biotechnology is using the patented NuGenerex Immuno-Oncology Ii-Key technology for a COVID-19 vaccine. They employ synthetic peptides that are chemically linked to the 4-amino acid li-Key to potentiate immune response.

**Live Vector Vaccines**

Live vector vaccines refer to live viruses that contain the complex antigen(s). These viral vectors are divided into two types: replicating (replicate in the host’s body) and non-replicating. The presence of heterogeneous antigens in live viruses can cause robust immunogenicity, but its safety is comparable to that of subunit vaccines. Adenoviral vectors are the most common delivery vehicles in gene therapy. They are non-enveloped double-stranded DNA viruses causing mild self-limiting respiratory tract infections in humans. Adenoviral vector-based vaccines have some advantages over mRNA vaccines, including low cost, thermostability, and ease of scale-up. Currently, Oxford/AstraZeneca and Johnson & Johnson are using adenoviral vectors for encoding the full-length S protein of SARS-CoV-2. The efficiency of these vaccines is relatively high, but they may not be effective in people with recessive infectious viruses.

COVID-19 Vaccine and Challenges due to SARS-COV-2 Variants

One of the major issues facing global health is the emergence of various variants of the coronavirus. For instance, even within a year, several variants appeared in different countries, such as the United Kingdom, South Africa, and Brazil. It has been shown that mutations can influence transmission rates, susceptibility to mAbs, and vaccine-induced neutralization of antibodies. However, current variants cannot entirely resist the existing vaccines due to the similarity of the antigenicity with the original virus. Thus, extensive vaccination of populations with available vaccines is needed, besides developing new vaccines with high efficacy against variants. The main target for designing COVID-19 vaccines is the S protein of the virus. Although mutations in the S protein may affect the efficacy of original vaccines, the development of vaccines for the variants is always based on targeting the S protein. Fortunately, updating nucleic acid vaccine, protein subunit vaccine, and adenoviral vector-based vaccine for new variants is easy and can be achieved by adjusting the gene sequence of
the S protein. In the fight against variants, three principles should be observed: (i) designing new vaccines based on the original vaccine to maintain immunological memory fresh, (ii) developing multivalent vaccines as they stimulate immunity against multiple variants and are preferred over monovalent vaccines, and (iii) re-vaccination with the initial vaccine is highly recommended to gain high titers of antibody. Therefore, institutions and pharmaceutical companies should collaborate to achieve high immunity against new variants and resolve practical limitations.114

Conclusion

Today we are faced with a dreadful virus with superior infectivity. To hold the spread of the virus, accelerating the diagnosis and treatment of patients is critical. It is essential that all the research centers, pharmaceutical companies, and governments collaborate to control this disease. Among antivirals, only remdesivir is approved by the FDA for hospitalized patients. Considering the NIH recommendation, adjuvant therapy with corticosteroids, JAK inhibitors, and IL-6 inhibitors can be helpful in severe cases to suppress the overactivation of immune cells. Furthermore, the use of anti-SARS-CoV-2 mAb products is recommended in non-hospitalized patients with mild to moderate COVID-19 at increased risk of clinical progression.

In contrast, other therapeutic agents can only be administered in clinical trials. Despite all the achievements in developing therapeutic strategies, we need to know a lot more about this virus and its complications to discover more effective treatments. In addition, further well-designed large sample studies are needed to prove the efficacy of these new therapeutic approaches and their safety. Thus far, it has been proven that vaccination is the most important weapon against COVID-19. To date, many vaccines have entered clinical trials, and the most successful vaccines are based on mRNA and adenoviral vectors. While emerging new variants can affect the efficacy of original vaccines, updating these vaccines can be done quickly if the genome sequence of the new variant is detected rapidly. To accelerate the process of overcoming this disease, the respective institutes and pharmaceutical companies should collaborate.

Authors’ Contribution

B.A, A.H.A.J, H.F, L.D, K.R.S, and H.F: Study concept and design, Acquisition, and interpretation of data, Drafting and critical revision of the manuscript. All authors have read and approved the final manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of Interest: None declared.

References

1 Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-60. doi: 10.1038/s41569-020-0360-5. PubMed PMID: 32139904; PubMed Central PMCID: PMCPMC7095524.

2 Netea MG, Giannarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, van Crevel R, van de Veerdonk FL, et al. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell. 2020;181:969-77. doi: 10.1016/j.cell.2020.04.042. PubMed PMID: 32437659; PubMed Central PMCID: PMCPMC7196902.

3 Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. doi: 10.1016/j.ijantimicag.2020.105938. PubMed PMID: 32171740; PubMed Central PMCID: PMCPMC7118659.

4 Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160:261-8. doi: 10.1111/imm.13223. PubMed PMID: 32460357; PubMed Central PMCID: PMCPMC7283723.

5 Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi: 10.1016/j.jaut.2020.102433. PubMed PMID: 32113704; PubMed Central PMCID: PMCPMC7283723.

6 Tufan A, Avanolgu Guler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-32. doi: 10.3906/sag-2004-168. PubMed PMID: 32299202; PubMed Central PMCID: PMCPMC7195984.

7 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi: 10.1016/S0140-6736(20)30183-5. PubMed
Abadi B, Aarabi Jeshvaghani AH, Fathalipour H, Dehghan L, Rahimi Sirjani K, Forootanfar H

PMID: 31986264; PubMed Central PMCID: PMCPMC1759299.

8 Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55. doi: 10.1183/13993003.00607-2020. PubMed PMID: 32269085; PubMed Central PMCID: PMCPMC7144260.

9 Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008;133:13-9. doi: 10.1016/j.virusres.2007.02.014. PubMed PMID: 17374415; PubMed Central PMCID: PMCPMC7114310.

10 Jacques FH, Apedaile E. Immunopathogenesis of COVID-19: Summary and Possible Interventions. Front Immunol. 2020;11:564925. doi: 10.3389/fimmu.2020.564925. PubMed PMID: 33072103; PubMed Central PMCID: PMCPMC7535345.

11 Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55:105923. doi: 10.1016/j.ijantimicag.2020.105923. PubMed PMID: 32070753; PubMed Central PMCID: PMCPMC7134866.

12 Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3:722-7. doi: 10.1016/s1473-3099(03)00806-5. PubMed PMID: 14592603; PubMed Central PMCID: PMCPMC7128816.

13 Salata C, Calisti A, Parolin C, Baritussio A, Palu G. Antiviral activity of cationic amphiphilic drugs. Expert Rev Anticancer Ther. 2017;15:483-92. doi: 10.1080/1474727210.2017.1305888. PubMed PMID: 28286997; PubMed Central PMCID: PMCPMC7103695.

14 Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1476-422X-2-69. PubMed PMID: 16115318; PubMed Central PMCID: PMCPMC1232869.

15 Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020. doi: 10.1101/2020.04.10.20060558.

16 Axford C, Schmitt AM, Janaidu P, Van’t Hoff J, Abd-Elsalam S, Abd EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12:2349. doi: 10.1038/s41467-021-22446-z. PubMed PMID: 33859192; PubMed Central PMCID: PMCPMC8050319.

17 Arabi YM, Shahroubi S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clin Infect Dis. 2020;70:1837-44. doi: 10.1093/cid/ciz544. PubMed PMID: 31925415; PubMed Central PMCID: PMCPMC7108209.

18 Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995-2005. doi: 10.1056/NEJMoa030634. PubMed PMID: 12671061.

19 Gong WJ, Zhou T, Wu SL, Ye JL, Xu JQ, Zeng F, et al. A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19. J Infect Chemother. 2021;27:876-81. doi: 10.1016/j.jiac.2021.02.018. PubMed PMID: 33676844; Pubmed Central PMCID: PMCPMC7894089.

20 Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252-6. doi: 10.1136/thorax.2003.012658. PubMed PMID: 14985565; PubMed Central PMCID: PMCPMC1746980.

21 Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir/ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health. 2021;14:740-8. doi: 10.1016/j.jiph.2021.03.015. PubMed PMID: 34020215; PubMed Central PMCID: PMCPMC8056786.

22 Amani B, Khanijahani A, Amani B, Hashemi P. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2021:24:246-57. doi: 10.18433/jpps31668. PubMed PMID: 34048671.

23 Bhattacharyya A, Kumar S, Sarma P, Kaur H, Prajapat M, Shekhar N, et al. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol. 2020;52:313-23. doi: 10.4103/ijp.IJP_627_20. PubMed PMID: 33078733; PubMed Central PMCID: PMCPMC7722914.

24 McCreary EK, Angus DC. Efficacy...
of Remdesivir in COVID-19. JAMA. 2020;324:1041-2. doi: 10.1001/jama.2020.16337. PubMed PMID: 32821934.

25 Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021;11:e048416. doi: 10.1136/bmjopen-2020-048416. PubMed PMID: 34168031; PubMed Central PMCID: PMCPMC8228818.

26 Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222. doi: 10.1038/s41467-019-13940-6. PubMed PMID: 31924756; PubMed Central PMCID: PMCPMC6954302.

27 Vitiello A, Ferrara F, Porta R. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;190:1637-8. doi: 10.1007/s11845-020-02488-2. PubMed PMID: 33943843; PubMed Central PMCID: PMCPMC7801863.

28 National Institute of Health [Internet]. Remdesivir. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/.

29 Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813-26. doi: 10.1056/NEJMoa2031994. PubMed PMID: 32445440; PubMed Central PMCID: PMCPMC7262788.

30 National Institute of Health [Internet]. Therapeutic Management of Hospitalized Adults With COVID-19. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults-therapeutic-management/.

31 Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazarian V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384:795-807. doi: 10.1056/NEJMoa2031994. PubMed PMID: 33306283; PubMed Central PMCID: PMCPMC7745180.

32 Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, et al. Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. Clin Infect Dis. 2021;73:e3996-e4004. doi: 10.1093/cid/ciaa1466. PubMed PMID: 33031500; PubMed Central PMCID: PMCPMC7797739.

33 Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020;6:1192-8. doi: 10.1016/j.eng.2020.03.007. PubMed PMID: 32346491; PubMed Central PMCID: PMCPMC7185795.

34 Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrob Agents Chemother. 2020;64. doi: 10.1128/AAC.01897-20. PubMed PMID: 32958718; PubMed Central PMCID: PMCPMC7674035.

35 Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. PubMed PMID: 32113509; PubMed Central PMCID: PMCPMC7102614.

36 Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400-2. doi: 10.1016/S1473-3099(20)30132-8. PubMed PMID: 32113509; PubMed Central PMCID: PMCPMC7158903.

37 Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, et al. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021;11:100755. doi: 10.1016/j.cegh.2021.100755. PubMed PMID: 33969237; PubMed Central PMCID: PMCPMC8088409.

38 Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407-18. doi: 10.1016/S2213-2600(21)00331-3. PubMed PMID: 34480861; PubMed Central PMCID: PMCPMC8409066.

39 Guimaraes PO, Quirk D, Furtado RH, Maia LN, Sarafia JF, Antunes MO, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;385:406-15. doi: 10.1056/NEJMoa2101643. PubMed
PMID: 34133856; PubMed Central PMCID: PMCPMC8220898.

40 National Institute of Health [Internet]. Kinase Inhibitors: Janus Kinase Inhibitors and Bruton's Tyrosine Kinase Inhibitors. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/

41 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323:1824-36. doi: 10.1001/jama.2020.6019. PubMed PMID: 32282022.

42 Hui DS. Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection. Am J Respir Crit Care Med. 2018;197:700-1. doi: 10.1164/rccm.201712-2371ED. PubMed PMID: 29227752.

43 Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51:98-102. doi: 10.1016/j.jinf.2004.09.008. PubMed PMID: 16038758; PubMed Central PMCID: PMCPMC7132384.

44 Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212:416-20. doi: 10.5694/mja2.50577. PubMed PMID: 32266987; PubMed Central PMCID: PMCPMC7262211.

45 Biful WL, Moore FA, Moore EE, Haenel JB, McIntyre RC, Jr., Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg. 1995;170:591-5. doi: 10.1016/s0002-9610(99)80022-1. PubMed PMID: 7492007.

46 Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalo P, et al. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Front Med (Lausanne). 2020;7:170. doi: 10.3389/fmed.2020.00170. PubMed PMID: 32391369; PubMed Central PMCID: PMCPMC7190300.

47 Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683-4. doi: 10.1016/S0140-6736(20)30361-5. PubMed PMID: 32122468; PubMed Central PMCID: PMCPMC7159292.

48 Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693-704. doi: 10.1056/NEJMoa2102436. PubMed PMID: 32678530; PubMed Central PMCID: PMCPMC7383595.

49 Piccica M, Lagi F, Trotta M, Spinicci M, Zamarchi L, Bartoloni A, et al. High-dose steroids for the treatment of severe COVID-19. Intern Emerg Med. 2021;16:1395-9. doi: 10.1007/s11739-021-02707-x. PubMed PMID: 33856664; PubMed Central PMCID: PMCPMC8047517.

50 National Institute of Health [Internet]. Corticosteroids. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/

51 Tuccioni M, Convertino I, Ferraro S, Valdiserra G, Cappello E, Fini E, et al. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021;16:1403-14. doi: 10.1080/17460441.2021.1960819. PubMed PMID: 34304682; PubMed Central PMCID: PMCPMC8353660.

52 Marovich M, Mascola JR, Cohen MS. Monoclonal Antibodies for Prevention and Treatment of COVID-19. JAMA. 2020;324:131-2. doi: 10.1001/jama.2020.10245. PubMed PMID: 32539093.

53 Food and Drug Administration [Internet]. Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. c2021. Available from: https://www.fda.gov/media/145802/download

54 Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325:1015. doi: 10.1001/jama.2021.1225. PubMed PMID: 33544136.

55 Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnner T, et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021;8:254. doi: 10.1093/ofid/ofab254. PubMed PMID: 34250192; PubMed Central PMCID: PMCPMC8241472.

56 Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. PubMed
Therapeutic strategies for COVID-19 patients

57 Febbraio MA, Rose-John S, Pedersen BK. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther. 2010;87:396-8. doi: 10.1038/clpt.2010.1. PubMed PMID: 20305672.

58 Gordon AC, Angus DC, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply. N Engl J Med. 2021;385:1147-9. doi: 10.1056/NEJMc2108482. PubMed PMID: 34407335.

59 Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-45. doi: 10.1016/S0140-6736(21)00676-0. PubMed PMID: 33933206; PubMed Central PMCID: PMCPMC8084355.

60 Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384:1503-16. doi: 10.1056/NEJMoa2028700. PubMed PMID: 33631066; PubMed Central PMCID: PMCPMC7953459.

61 National Institute og Health [Internet]. Interleukin-6 Inhibitors: 2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/

62 Du J, Li H, Lian J, Zhu X, Qiao L, Lin J. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury. Stem Cell Res Ther. 2020;11:192. doi: 10.1186/s13287-020-01699-3. PubMed PMID: 32448377; PubMed Central PMCID: PMC7245626.

63 Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci. 2015;1351:114-26. doi: 10.1111/nyas.12815. PubMed PMID: 26152292.

64 Ben-Mordechai T, Palevski D, Glucksman-Galnoy Y, Elron-Gross I, Margalit R, Leor J. Targeting macrophage subsets for infarct repair. J Cardiovasc Pharmacol Ther. 2015;20:36-51. doi: 10.1177/1074284415434916. PubMed PMID: 24938456.

65 Cardenes N, Aranda-Valderrama P, Carney JP, Sellares Torres J, Alvarez D, Kocyildirim E, et al. Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model. BMJ Open Respir Res. 2019;6:e000308. doi: 10.1136/bmjresp-2018-000308. PubMed PMID: 30713713; PubMed Central PMCID: PMC6339992.

66 Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39. doi: 10.1186/1465-9921-15-39. PubMed PMID: 24708472; PubMed Central PMCID: PMC3994204.

67 Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67:1-8. doi: 10.1111/j.1600-0897.2011.01069.x. PubMed PMID: 21951555.

68 Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007;28:219-26. doi: 10.1016/j.it.2007.03.001. PubMed PMID: 17400510.

69 Basiri A, Pazhouhnia Z, Beheshtizadeh N, Hoseinpour M, Saghazadeh A, Rezaei N. Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises. Stem Cell Rev Rep. 2021;17:163-75. doi: 10.1007/s12015-020-09994-5. PubMed PMID: 32564256; PubMed Central PMCID: PMC7305935.

70 Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11:216-28. doi: 10.14336/AD.2020.0228. PubMed PMID: 32257537; PubMed Central PMCID: PMC7069465.

71 Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells. 2020;9. doi: 10.3390/cells9040924. PubMed PMID: 33189639; PubMed Central PMCID: PMC7226831.

72 Rezakhani L, Kelishadrokhi AF, Soleimanizadeh A, Rahmati S. Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises. Chem Phys Lipids. 2021;234:105009. doi: 10.1016/j.chemphyslip.2020.105009. PubMed PMID: 33189639; PubMed Central PMCID: PMC7658620.

73 Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398-400. doi:
10.1016/S1473-3099(20)30141-9. PubMed PMID: 32133510; PubMed Central PMCID: PMCPMC7128218.

74 Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020;40:416-37. doi: 10.1002/phar.2398. PubMed PMID: 32253318; PubMed Central PMCID: PMCPMC7196837.

75 Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117:9490-6. doi: 10.1073/pnas.2004168117. PubMed PMID: 32253318; PubMed Central PMCID: PMCPMC7196837.

76 Rojas M, Rodriguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19:102554. doi: 10.1016/j.autrev.2020.102554. PubMed PMID: 32380316; PubMed Central PMCID: PMCPMC7198427.

77 Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59:102790. doi: 10.1016/j.transci.2020.102790. PubMed PMID: 33523609; PubMed Central PMCID: PMCPMC7821984.

78 Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021;384:1015-27. doi: 10.1056/NEJMoa2031893. PubMed PMID: 33523609; PubMed Central PMCID: PMCPMC7821984.

79 Klassen SA, Senefeld J, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. medRxiv. 2021. doi: 10.1101/2020.07.29.20162917. PubMed PMID: 33140056; PubMed Central PMCID: PMCPMC7605561.

80 Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS, et al. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021;10. doi: 10.7554/eLife.69866. PubMed PMID: 34085928; PubMed Central PMCID: PMCPMC8020548.

81 Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18. doi: 10.1038/s41392-020-0127-9. PubMed PMID: 32296012; PubMed Central PMCID: PMCPMC7035340.

82 Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757-65. doi: 10.1172/JCI138745. PubMed PMID: 32254064; PubMed Central PMCID: PMCPMC7259988.

83 O’Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021;131. doi: 10.1172/JCI150646. PubMed PMID: 33974559; PubMed Central PMCID: PMCPMC8245169.

84 Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7:CD013600. doi: 10.1002/14651858. CD013600.pub2. PubMed PMID: 32648959; PubMed Central PMCID: PMCPMC7389743.

85 Bakhtawar N, Usman M, Khan MMU. Convalescent Plasma Therapy and Its Effects On COVID-19 Patient Outcomes: A Systematic Review of Current Literature. Cureus. 2020;12:e9535. doi: 10.7759/cureus.9535. PubMed PMID: 32905148; PubMed Central PMCID: PMCPMC7465934.

86 World Health Organization [Internet]. COVID-19 vaccine tracker and landscape. c2021. [updated 24 Oct 2021]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

87 World Health Organization [Internet]. 7 Vaccines Approved for Use by WHO. c2021. [updated 1 Nov 2021]. Available from: https://covid19.trackvaccines.org/agency/who/

88 Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508-17. doi: 10.1016/j.csbj.2021.04.061. PubMed PMID: 33936564; PubMed Central PMCID: PMCPMC8076774.

89 Food and Drug Administration [Internet]. COVID-19 Vaccines. c2021 [updated 24 Oct 2021]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines

90 Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines.
Therapeutic strategies for COVID-19 patients

91 Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012;11:1405-13. doi: 10.1586/erv.12.126. PubMed PMID: 23252385; PubMed Central PMCID: PMCPMC3360073.

92 Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85:12201-15. doi: 10.1128/JVI.06048-11. PubMed PMID: 21937658; PubMed Central PMCID: PMCPMC3209347.

93 Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7:e35421. doi: 10.1371/journal.pone.0035421. PubMed PMID: 22536382; PubMed Central PMCID: PMCPMC3335060.

94 Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with SARS coronavirus vaccines is associated with enhanced hepatitis in ferrets. J Virol. 2004;78:12672-6. doi: 10.1128/JVI.78.22.12672-12676.2004. PubMed PMID: 15507655; PubMed Central PMCID: PMCPMC525089.

95 Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892:173751. doi: 10.1016/j.ejphar.2020.173751. PubMed PMID: 3245898; PubMed Central PMCID: PMCPMC7525089.

96 Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288:198114. doi: 10.1016/j.virusres.2020.198114. PubMed PMID: 32800805; PubMed Central PMCID: PMCPMC7423510.

97 Liang JG, Su D, Song TZ, Zeng Y, Huang W, Wu J, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12:1346. doi: 10.1038/s41467-021-21634-1. PubMed PMID: 33649323; PubMed Central PMCID: PMCPMC7921634.

98 Tian JH, Patel N, Hautp L, Zhou H, Weston S, Hammond H, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12:372. doi: 10.1038/s41467-020-20653-8. PubMed PMID: 33446655; PubMed Central PMCID: PMCPMC7809486.

99 Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17:613-20. doi: 10.1038/s41467-020-0400-4. PubMed PMID: 33203189; PubMed Central PMCID: PMCPMC7091888.

100 Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21:1107-19. doi: 10.1016/S1473-3099(21)00127-4. PubMed PMID: 33773111; PubMed Central PMCID: PMCPMC7990482.

101 Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261-79. doi: 10.1038/nrd.2017.243. PubMed PMID: 29326426; PubMed Central PMCID: PMCPMC5906799.

102 Liu MA. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019;7. doi: 10.3390/vaccines7020037. PubMed PMID: 31022829; PubMed Central PMCID: PMCPM6631684.

103 Shafaati M, Saidijam M, Soleimani M, Hazrati F, Mirzaei R, Amirheidari B, et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol. 2021. doi: 10.2217/fvl-2021-0170. PubMed PMID: 34858516; PubMed Central PMCID: PMCPMC8692371.

104 Sheridan C. First COVID-19 DNA vaccine approved, others in hot pursuit. Nat Biotechnol. 2021;39:1479-82. doi: 10.1038/d41587-021-00023-5. PubMed PMID: 34785814.

105 Azmi F, Ahmad Fuaad AA, Skwarczynski M, Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother. 2014;10:778-96. doi: 10.4161/hv.27332. PubMed PMID:
24300669; PubMed Central PMCID: PMCPMC4130256.

106 Ahmed SF, Quadeer AA, McKay MR. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses. 2020;12. doi: 10.3390/v12030254. PubMed PMID: 32106567; PubMed Central PMCID: PMCPMC7150947.

107 Rahman MS, Hoque MN, Islam MR, Akter S, Rubayet Ul Alam ASM, Siddique MA, et al. Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach. PeerJ. 2020;8:e9572. doi: 10.7717/peerj.9572. PubMed PMID: 33194329; PubMed Central PMCID: PMCPMC7394063.

108 Lukashev AN, Zamyatin AA, Jr. Viral Vectors for Gene Therapy: Current State and Clinical Perspectives. Biochemistry (Mosc). 2016;81:700-8. doi: 10.1134/S0006297916070063. PubMed PMID: 27449616.

109 Holm MR, Poland GA. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectorized COVID-19 vaccines for optimal efficacy. Vaccine. 2021;39:457-9. doi: 10.1016/j.vaccine.2020.12.017. PubMed PMID: 33339671; PubMed Central PMCID: PMCPMC7723768.

110 Mendonca SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021;6:97. doi: 10.1038/s41541-021-00356-x. PubMed PMID: 34354082; PubMed Central PMCID: PMCPMC8342436.

111 Mahase E. Covid-19: How many variants are there, and what do we know about them? BMJ. 2021;374:n1971. doi: 10.1136/bmj.n1971. PubMed PMID: 34413059.

112 Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409-24. doi: 10.1038/s41579-021-00573-0. PubMed PMID: 34075212; PubMed Central PMCID: PMCPMC8167834.

113 Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KRR. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 2021;137:111254. doi: 10.1016/j.biopha.2021.111254. PubMed PMID: 33550049; PubMed Central PMCID: PMCPMC7843096.

114 Zhou W, Wang W. Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. Signal Transduct Target Ther. 2021;6:226. doi: 10.1038/s41392-021-00644-x. PubMed PMID: 34108440; PubMed Central PMCID: PMCPMC8187888.